<DOC>
	<DOCNO>NCT00556088</DOCNO>
	<brief_summary>This phase I protocol evaluate safety tolerability combination LBH589 paclitaxel/carboplatin . The combination LBH589 , paclitaxel/carboplatin , bevacizumab also evaluate tolerability preliminary antitumor activity subset patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>LBH589 , Paclitaxel , Carboplatin +/- Bevacizumab Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically document metastatic locally advanced , incurable malignancy paclitaxel carboplatin clinically appropriate example , nonsmall cell lung , breast , ovarian , head neck cancer , carcinoma unknown primary . 2 . Male female patient age &gt; = 18 year old . 3 . Maximum 3 prior regimen metastatic setting allow may include targeted agent , immunotherapy chemotherapy . 4 . Measurable disease RECIST criterion . 5 . ECOG PS 0 1 . 6 . Laboratory value follow : ANC &gt; = 1500/μL Hgb &gt; = 9 g/dL Platelets &gt; = 100,000/uL Bilirubin &lt; = upper limit normal ( ULN ) AST/SGOT ALT/SGPT &lt; = 2.5 x ULN &lt; = 5.0 x ULN patient liver metastasis Creatinine &lt; = 2.0 mg/dL Or 24hour Creatinine Clearance &gt; = 50 ml/min Albumin &gt; = 3 g/dL Potassium &gt; = low limit normal ( LLN ) Phosphorous &gt; = LLN Calcium &gt; = LLN Magnesium &gt; = LLN PT/INR PTT &lt; = 1.5 x ULN 7 . Peripheral neuropathy &lt; grade 1 . 8 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . 9 . Life expectancy &gt; 12 week . 10 . Accessible treatment followup . 11 . All patient must able understand nature study give write informed consent prior study entry . 1 . Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment 2 . Impaired cardiac function include follow : Screening ECG QTc &gt; 450 msec . Congenital long QT syndrome . History sustain ventricular tachycardia . Any history ventricular fibrillation torsades de pointes . Bradycardia define heart rate &lt; 50 beat per minute . Patients wit pacemaker heart rate &gt; = 50 beat per minute eligible . Myocardial infarction unstable angina within 6 month study entry . Congestive heart failure ( NY Heart Association class III IV [ See Appendix B ] ) . Right bundle branch block leave anterior hemiblock ( bifasicular block ) . Atrial fibrillation flutter . 3 . Uncontrolled hypertension ( systolic blood pressure [ BP ] 160 diastolic BP &gt; 95mm Hg ) uncontrolled cardiac arrhythmia . 4 . Active CNS disease , include meningeal metastasis . 5 . Known diagnosis human immunodeficiency virus ( HIV ) infection . 6 . Unresolved diarrhea &gt; CTCAE grade 1 . 7 . Chemotherapy , investigational drug therapy , major surgery &lt; 4 week prior start study drug patient recover side effect previous therapy . 8 . Patient &lt; 5 year free another primary malignancy except primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . 9 . Concomitant use anticancer therapy radiation therapy . 10 . Women pregnant breast feed woman childbearing potential ( WOCBP ) willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within 7 day first administration oral LBH589 . 11 . Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . One method must condom . 12 . Patients gastrointestinal ( GI ) tract disease , cause inability take oral medication , malabsorption syndrome , requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) . 13 . Other concurrent severe , uncontrolled infection intercurrent illness , include limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 14 . Patients uncontrolled coagulopathy . 15 . Abnormal thyroid function ( TSH free T4 ) detect screening.Patients know hypothyroidism stable thyroid replacement eligible . Exclusion Criteria ( Part II portion ) 1 . Patients tumor type advance nonsmall cell lung cancer patient squamous cell histology nonsmall cell lung cancer . 2 . Patients major surgical procedure ( include mediastinoscopy ) , open biopsy , significant traumatic injury within 68 week begin bevacizumab . Fine needle aspiration , core biopsy , mediastinoscopy minor surgical procedure within 7 day begin bevacizumab . 3 . Patients receive fulldose oral parenteral anticoagulation . Patients receive thrombolytic therapy within 10 day start bevacizumab also ineligible . Patients may receive anticoagulation therapy , ( 1 mg coumadin daily ) port clot prophylaxis . 4 . Patients serious nonhealing wound , ulcer , bone fracture . 5 . Patients evidence bleed diathesis coagulopathy . 6 . Patients history hemoptysis ( define bright red blood ½ teaspoon per episode ) within 3 month prior study enrollment . 7 . History myocardial infarction unstable angina within 6 month first bevacizumab dose . 8 . Patients proteinuria screen demonstrate either : a. Urine protein creatinine ( UPC ) ration &gt; 1.0 screening OR b. Urine dipstick proteinuria &gt; 2+ ( patient discover &gt; 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; 1 g protein 24 hour eligible . 9 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior begin bevacizumab . 10 . History stroke transient ischemic attack within 6 month prior first bevacizumab dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>LBH589</keyword>
	<keyword>Phase I</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Dose escalation</keyword>
</DOC>